» Articles » PMID: 28485522

Effects of 1-month Withdrawal of Ventilatory Support in Hypercapnic Myotonic Dystrophy Type 1

Overview
Journal Respirology
Specialty Pulmonary Medicine
Date 2017 May 10
PMID 28485522
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: The benefits of domiciliary non-invasive ventilation (NIV) in myotonic dystrophy type 1 (DM1) are unclear. We sought to determine the effects of elective discontinuation of ventilatory support for 1 month in DM1 patients receiving NIV for chronic hypercapnic respiratory failure.

Methods: At baseline, 12 patients underwent polysomnography, and assessment of subjective (Epworth Sleepiness Scale) and objective (Oxford Sleep Resistance Test) sleepiness, fatigue (Fatigue Severity Scale), respiratory function including muscle strength, arterial blood gas (ABG), hypercapnic ventilatory response (HCVR), Blood Pressure, peripheral arterial tonometry (PAT) and pulse wave velocity (PWV). They also completed the SF36. Testing was repeated (Visit 2) 1 month after elective cessation of NIV and again (Visit 3) 1 month after NIV reintroduction.

Results: No changes were seen in SF36, sleepiness or fatigue, respiratory function, muscle strength nor HCVR. Likewise, there were no changes in Blood Pressure, PAT or PWV. Mean nocturnal SpO deteriorated off NIV and improved on resumption (mean ± SD = 95.02 ± 1.90%, 92.23 ± 3.61% and 95.08 ± 2.28%, P = 0.006 change Visit 1 to Visit 2, 0.009 Visit 2 to Visit 3). Daytime PaCO (arterial partial pressure of carbon dioxide) was 43.13 ± 4.20 mm Hg, 46.28 ± 2.25 mm Hg and 43.87 ± 2.85 mm Hg, P = 0.056 and 0.017 over the same intervals.

Conclusion: DM1 patients derive little benefit in symptoms or quality of life from NIV. Nocturnal and diurnal ventilatory functions deteriorate slightly off NIV for 1 month, but this does not appear to be due to changes in HCVR or respiratory function. HCVR changes may be of primary CNS origin given stability on or off NIV.

Citing Articles

Development of prediction models based on respiratory assessments to determine the need for non-invasive ventilation in patients with myotonic dystrophy type 1.

Lizio A, Pirola A, Ferrari C, Mauro L, Falcier E, Sansone V Neurol Sci. 2023; 44(6):2149-2157.

PMID: 36694070 DOI: 10.1007/s10072-023-06631-0.


Assessment of Respiratory Function and Need for Noninvasive Ventilation in a Cohort of Patients with Myotonic Dystrophy Type 1 Followed at One Single Expert Center.

Ferrari Aggradi C, Falcier E, Lizio A, Pirola A, Casiraghi J, Zanolini A Can Respir J. 2022; 2022:2321909.

PMID: 35762008 PMC: 9233572. DOI: 10.1155/2022/2321909.


The role of noninvasive ventilation in the management of type II respiratory failure in patients with myotonic dystrophy.

Rautemaa V, Roberts M, Bentley A, Felton T ERJ Open Res. 2021; 7(3).

PMID: 34322542 PMC: 8311128. DOI: 10.1183/23120541.00192-2020.


Noninvasive Home Mechanical Ventilation in Adult Myotonic Dystrophy Type 1: A Systematic Review.

Vosse B, Seijger C, Cobben N, van Engelen B, van Kuijk S, Faber C Respiration. 2021; 100(8):816-825.

PMID: 33965950 PMC: 8491482. DOI: 10.1159/000515453.


Management of respiratory complications and rehabilitation in individuals with muscular dystrophies: 1st Consensus Conference report from UILDM - Italian Muscular Dystrophy Association (Milan, January 25-26, 2019).

Rao F, Garuti G, Vitacca M, Banfi P, Racca F, Cutrera R Acta Myol. 2021; 40(1):8-42.

PMID: 33870094 PMC: 8033426. DOI: 10.36185/2532-1900-045.